This site is intended for health professionals only

Unique formulation of naproxen passes Phase I

teaser

Phase I results for a unique formulation of the anti-inflammatory painkiller naproxen have been announced.

Iroko Pharmaceuticals has developed a new form of the widely used pain medication with its proprietary, patented nanotechnology.

The comparator products used in this Phase I pharmacokinetic study of naproxen were identified as Naprosyn® and EC-Naprosyn®, a currently marketed enteric-coated brand of naproxen.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Naproxen is a non-steroidal anti-inflammatory drug (NSAID) commonly used for the reduction of pain, fever, inflammation and stiffness caused by osteoarthritis among other conditions.

Iroko is a pharmaceutical company committed to the development and commercialization of currently marketed pharmaceutical products in specialty therapeutic areas.

EC-Naprosyn® and Naprosyn® are registered trademarks of Syntex Pharmaceuticals International Limited.






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x